US 12,285,474 B2
Vsg-based vaccination and antibody generation platform for the treatment of diseases
Fotini Nina Papavasiliou, Heidelberg (DE); Hamidreza Hashemi, Heidelberg (DE); Gianna Triller, Heidelberg (DE); Erec Stebbins, Heidelberg (DE); Aubry Miller, Heidelberg (DE); and Andreas Baumann, Heidelberg (DE)
Assigned to Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Heidelberg (DE)
Appl. No. 17/288,208
Filed by Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Heidelberg (DE)
PCT Filed Oct. 24, 2019, PCT No. PCT/EP2019/079063
§ 371(c)(1), (2) Date Apr. 23, 2021,
PCT Pub. No. WO2020/084072, PCT Pub. Date Apr. 30, 2020.
Claims priority of application No. 18202305 (EP), filed on Oct. 24, 2018.
Prior Publication US 2021/0401956 A1, Dec. 30, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 39/385 (2006.01)
CPC A61K 39/0013 (2013.01) [A61K 39/385 (2013.01); A61K 2039/521 (2013.01); A61K 2039/523 (2013.01); A61K 2039/545 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/6075 (2013.01)] 11 Claims
OG exemplary drawing
 
1. An antigenic particle coated with an engineered variant surface glycoprotein (eVSG), wherein the eVSG comprises a VSG linked to an immunogenic compound, wherein the immunogenic compound is a small molecular drug, and which is covalently linked via a linker to the N-terminus of the VSG, wherein the VSG is VSG3 derived from the genome of T. brucei.